TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11367869
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of vitamin E (400 mg t.i.d.) plus standard treatment
Study: 3676625
Drug: Day hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day hospital treatment (psychotherapy)
Study: 3676625
Drug: Day hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day hospital treatment (all forms of day care)
Study: 23257314
Drug: 3-mg po
Normalized name: lusutrombopag 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-mg po mibampator
Study: 22001199
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg glucosamine sulfate
Study: 15851238
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI)
Study: 15851238
Drug: No angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI)
Study: 15851238
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI) in patients with congestive heart failure or impaired left ventricular function
Study: 2752739
Drug: Commercial cream
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial cream containing 6% purified lanolin
Study: 1157005
Drug: 6-mercaptopurine (6MP)
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine (6MP) (75 mg/m2/day)
Study: 1157005
Drug: methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate (MTX) (25 mg/m2/twice weekly)
Study: 1157005
Drug: cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide (CYC) (100 mg/m2/day)
Study: 21741088
Drug: Concurrent immunomodulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent immunomodulator use (purine antimetabolites or methotrexate)
Study: 21741088
Drug: Development of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development of antibodies to infliximab (ATIs)
Study: 17645255
Drug: Simple oral
Normalized name: Simple Oral Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple oral administration of Wenlafaxin
Study: 11355435
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment using local points ST‐6, ST‐7, SI‐18, GV‐20, GB‐20, BL‐10 and distant point LI‐4, with needles manipulated to achieve De‐qui sensation and left in situ for 30 min, administered weekly for a total of six treatments.
Study: 9663368
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg-felodipine ER 2.5 mg once daily, titrated to a maximum of enalapril 10 mg-felodipine ER 10 mg if SiDBP not controlled after 4 weeks; Hydrochlorothiazide (HCTZ) 12.5 mg added if hypertension not controlled at maximum dose.
Study: 9663368
Drug: Enalapril-felodipine ER
Normalized name: enalapril / felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril-felodipine ER combination with HCTZ 12.5 mg
Study: 2571216
Drug: CGP 17582
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 17582 B (50 mg orally)
Study: 2571216
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 mg orally)
Study: 28644774
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) with chemotherapy (two doses of GO during induction and intensification)
Study: 28644774
Drug: Standard five-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard five-course chemotherapy alone (No-GO arm)
Study: 28644774
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) with chemotherapy
Study: 26196193
Drug: ECMO ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECMO ± smoke inhalation acute lung injury (SALI)
Study: 17063425
Drug: Systemic bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Systemic bevacizumab (5 mg/kg), administered three times at 2-week intervals.
Study: 17063425
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1 mg), administered up to three times at 4-week intervals.
Study: 10320603
Drug: Patient Controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Controlled Analgesia (PCA) with background infusion (BI) at 15 microg x kg(‐1) x h(‐1) and bolus doses of 15 microg x kg(‐1) with a lock‐out interval of 10 min
Study: 10320603
Drug: Continuous Infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Infusion (CI) at 20 to 40 microg x kg(‐1) x h(‐1)
Study: 6412795
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg) plus Placebo
Study: 6412795
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg) plus Chlorthalidone (25 mg)
Study: 31808594
Drug: Ivermectin 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 0.4 mg/kg, orally, once 2 hours before infection
Study: 30153737
Drug: Comprehensive smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive smoking treatment including individual counseling, free pharmacotherapy (dual nicotine replacement therapy or varenicline), and 5 weeks of contingency management.
Study: 30153737
Drug: Delayed intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed intervention control sites (no treatment during the study period).
Study: 16611273
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg maintenance every 8 weeks
Study: 8869676
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion (mean rate 330 +/- 10 micrograms/kg/min)
Study: 1531487
Drug: All therapies
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All therapies (including manual therapy, physiotherapy, GP treatment, and placebo)
Study: 6845352
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg (divided doses)
Study: 6845352
Drug: Ethanol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (50 ml/70 kg body weight)
Study: 31810456
Drug: Free paracetamol
Normalized name: Soul Pattinson Colour Free Paracetamol Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free paracetamol distribution (experimental arm)
Study: 27442691
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus contingency management (STCM)
Study: 27442691
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (STA)
Study: 25196301
Drug: Synbiotic bread
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic bread (Lactobacillus sporogenes 1 × 10(8) CFU, 0.07 g inulin per 1 g)
Study: 22615088
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation phone call from a medical resident within 72 hours after discharge
Study: 12011970
Drug: HR (Paroven,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR (Paroven, Venoruton; 0‐(beta‐hydroxyethyl)‐rutosides), 1g sachets, twice daily, for 4 weeks
Study: 2319479
Drug: Caffeine 56
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 56 mg
Study: 2319479
Drug: Caffeine 18
Normalized name: Acetaminophen/Aspirin/Caffeine 180 MG-230 MG-15 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 18 mg
Study: 2319479
Drug: Caffeine 10
Normalized name: caffeine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 10 mg
Study: 377152
Drug: 2g metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2g metronidazole rectal suppositories
Study: 31787562
Drug: ω‐3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 PUFAs (2 g twice daily)
Study: 31787562
Drug: ω‐3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 PUFAs + NX (220 mg twice daily)
Study: 31787562
Drug: NX (220 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX (220 mg twice daily)
Study: 21068692
Drug: Separate Hib-TT
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate Hib-TT and MenC-CRM197 vaccines
Study: 11704315
Drug: 200 mg/m(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m(2) amifostine i.v. 30 min before radiation
Study: 9033316
Drug: Heparin-coated cardiopulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated cardiopulmonary bypass circuit
Study: 8345794
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy (conjugated equine estrogens, 0.625 mg/d continuous + levonorgestrel, 0.075 mg/d for 12 days of each 28‐day cycle)
Study: 8345794
Drug: Transdermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapy (estradiol 17 beta, 0.05 mg/d continuous + norethindrone acetate, 0.25 mg/d for 14 days of each 28‐day cycle)
Study: 27855699
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure Treatment for Adolescents (PE-A)
Study: 25885496
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 4 mL/kg (group L)
Study: 25885496
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 10 mL/kg (group H)
Study: 20685760
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group maintained usual daily activity level
Study: 10530408
Drug: T-cell receptor
Normalized name: T-cell receptor marker
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell receptor (TCR) gene rearrangements using primers hybridising to TCR delta and gamma genes
Study: 10530408
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all five primer sets
Study: 29920211
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rs6720173‐GG, rs3808607‐G, and rs760241‐A genotypes)
Study: 24401211
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs (2 g/day for 12 weeks)
Study: 22206609
Drug: Low-tube voltage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-tube voltage (80 kVp) 320-detector row volume CT angiography (L-VCTA)
Study: 11811169
Drug: i.v. CRF
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. CRF as a 1.0-microg/kg bolus followed by a constant infusion (1.0 microg/kg/h)
Study: 2405994
Drug: Transurethral debulking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral debulking surgery combined with upfront CMV chemotherapy plus cisplatin and 4000 cGy
Study: 2405994
Drug: Neoadjuvant MCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant MCV chemotherapy for selective bladder preservation
Study: 31147359
Drug: Morita Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morita Therapy (MT)
Study: 27314331
Drug: Darmocare Pre(®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darmocare Pre(®) (prebiotic formulation)
Study: 25825102
Drug: 8% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% lignocaine gel
Study: 25825102
Drug: 15% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% lignocaine spray
Study: 21932114
Drug: Monthly minodronate
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly minodronate at 30 mg
Study: 21932114
Drug: Monthly minodronate
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly minodronate at 50 mg
Study: 21932114
Drug: Daily minodronate
Normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daily minodronate at 1 mg
Study: 21932114
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (30 mg, 50 mg, and 1 mg daily)
Study: 19188545
Drug: Gemcitabine-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine-based chemotherapy (gemcitabine plus carboplatin, paclitaxel, or cisplatin)
Study: 11725940
Drug: Daily records
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily records of physical activity (intervention group)
Study: 9164824
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Ca as AAACa after each meal and 450 mg at bedtime
Study: 9164824
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg after each meal
Study: 3111280
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 35% CO2 and 65% O2; Duration: Not specified
Study: 25880814
Drug: OXCAP-RT (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXCAP-RT (oxaliplatin 85 mg/m2 Day 1,15,29; capecitabine 625 mg/m2 twice daily on days of RT; RT-45 Gy/25 fractions/5 weeks)
Study: 25880814
Drug: CarPac-RT (Carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CarPac-RT (Carboplatin AUC2 and paclitaxel 50 mg/m2 Day 1,8,15,22,29; RT-45 Gy/25 fractions/5 weeks)
Study: 23674855
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa (N. sativa) administered for three months at a dose of 450 mg three times daily
Study: 21270583
Drug: Intradermal buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal buffered lidocaine
Study: 21270583
Drug: Intradermal bacteriostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal bacteriostatic normal saline
Study: 19207871
Drug: Standard vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vaccination protocol: three doses of 40 microg i.m. at months 0, 1 and 6
Study: 8602592
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO3) 1000 mg/d
Study: 8602592
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO3) 1000 mg/d plus 5 micrograms (200 IU) vitamin D/d
Study: 8602592
Drug: Milk (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (1 L more than usual daily diet)
Study: 8602592
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (three tablets daily)
Study: 20926016
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg/day for 4 weeks
Study: 20926016
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non‐placebo, non‐treatment)
Study: 19001742
Drug: FDP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDP 200 mg/kg infused intravenously before anesthesia
Study: 19001742
Drug: FDP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDP 200 mg/kg
Study: 16380703
Drug: Insulin-like Growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like Growth Factor-I (IGF-I)
Study: 16380703
Drug: Insulin-like Growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)
Study: 12417879
Drug: Albuterol MDI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDI (0 to 576 microg)
Study: 12417879
Drug: Albuterol MDI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDI (90 microg and 180 microg)
Study: 12417879
Drug: Albuterol MDI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDI
Study: 10599545
Drug: GnRH agonist/hMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH agonist/hMG
Study: 7547766
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (0.625 mg conjugated equine oestrogens with 0.15 mg cyclic norgestrel for 12 days per 28 day cycle)
Study: 1437059
Drug: Clotrimazole troches,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole troches, 10 mg, five times daily
Study: 1437059
Drug: Nystatin suspension,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin suspension, 500,000 units, four times daily
Study: 3980803
Drug: Trimethylpsoralen bath
Normalized name: 4,8,5'-Trimethylpsoralen
DrugBank: Trioxsalen (DB04571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethylpsoralen bath plus ultraviolet A (bath PUVA) combined with oral retinoid, etretinate (1 mg/kg/day)
Study: 3980803
Drug: Etretinate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (1 mg/kg/day)
Study: 3980803
Drug: Bath PUVA
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bath PUVA (maintenance therapy)
Study: 3980803
Drug: Etretinate (25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (25‐50 mg daily)
Study: 28228411
Drug: Dexamethasone implant
Normalized name: dexamethasone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone implant (DEX)
Study: 12764624
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy (2x850 mg/day for 8 weeks)
Study: 11527172
Drug: Inchin‐ko‐to (ICKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inchin‐ko‐to (ICKT) 0.15 g/kg per day administered orally for 1 year
Study: 7920930
Drug: Step-down protocol
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down protocol (FSH +/‐ hMG without LHRH agonist)
Study: 7920930
Drug: Step-up protocol
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up protocol (FSH +/‐ hMG without LHRH agonist)
Study: 7920930
Drug: Step-down protocol
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down protocol (FSH +/‐ hMG with LHRH agonist)
Study: 7920930
Drug: Step-up protocol
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up protocol (FSH +/‐ hMG with LHRH agonist)
Study: 3532967
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) 5 mg/kg daily
Study: 29407633
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant (control)
Study: 22747652
Drug: Perceived drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived drug treatment
Study: 22747652
Drug: Perceived placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived placebo treatment
Study: 15869544
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate (0.05%) applied once daily
Study: 15869544
Drug: Initial once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial once-daily followed by alternate-day application
Study: 28767570
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride 5mg (5mL)
Study: 28767570
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride 5mg (5mL)
Study: 25702400
Drug: Allapinine (ALP)
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allapinine (ALP) (1.5 mg/kg/d)
Study: 25702400
Drug: Quinidine bisulphate
Normalized name: quinidine bisulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine bisulphate (QUIN) (15 mg/kg/d)
Study: 18922712
Drug: Multiple injections
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injections of <0.5 ml 1% polidocanol foam
Study: 18922712
Drug: Few injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Few injections of >0.5 ml 1% polidocanol foam
Study: 17278196
Drug: Tegaserod (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod (6 mg b.i.d.)
Study: 15361727
Drug: Clarithromycin 30
Normalized name: lansoprazole/amoxicillin trihydrate/clarithromycin 30 mg-500 mg-500 mg ORAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 30 mg/kg/day b.i.d. for 5 days
Study: 15361727
Drug: Clarithromycin 15
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 15 mg/kg/day b.i.d. for 5 days
Study: 15361727
Drug: Amoxicillin/clavulanate 43.8/6.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 43.8/6.2 mg/kg/day b.i.d. for 5 days
Study: 15361727
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 30 mg/kg/day 3 times a day for 10 days
Study: 11603222
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of progesterone
Study: 11603222
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day of progesterone
Study: 11603222
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of progesterone